Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A Plus Biotechnology CoTPE:6918 -0.13%72 Return-on-Tangible-Equity is 12.45% as of Dec. 2025, which is 98% above its 10-year median of 6.30. GuruFocus rates TPE:6918 with a GF Score™ of 72/100 and a GF Value™ of NT$87.26 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 760 Medical Devices & Instruments companies, A Plus Biotechnology Co ranks better than 76.97% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. A Plus Biotechnology Co's annualized net income for the quarter that ended in Dec. 2025 was NT$156.0 Mil. A Plus Biotechnology Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$1,253.2 Mil. Therefore, A Plus Biotechnology Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 12.45%.
The historical rank and industry rank for A Plus Biotechnology Co's Return-on-Tangible-Equity or its related term are showing as below:
TPE:6918'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1.49 Med: 6.3 Max: 17.44
Current: 15.53
During the past 7 years, A Plus Biotechnology Co's highest Return-on-Tangible-Equity was 17.44%. The lowest was -1.49%. And the median was 6.30%.
TPE:6918's Return-on-Tangible-Equity is ranked better than 76.97% of 760
companies
in the Medical Devices & Instruments industry
Industry Median: 4.03
vs TPE:6918: 15.53
A Plus Biotechnology Co (TPE:6918) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
A Plus Biotechnology Co Return-on-Tangible-Equity Related Terms
A Plus Biotechnology Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for A Plus Biotechnology Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A Plus Biotechnology Co Return-on-Tangible-Equity Chart
TPE:6918 vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, A Plus Biotechnology Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
A Plus Biotechnology Co Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, A Plus Biotechnology Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where A Plus Biotechnology Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 12.45% mean?
A Plus Biotechnology Co (TPE:6918) has a Return-on-Tangible-Equity of 12.45% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on A Plus Biotechnology Co and its competitors. This is 98% above median its historical median of 6.30. According to the industry distribution chart, A Plus Biotechnology Co ranks #175 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 23%.
Is A Plus Biotechnology Co's Return-on-Tangible-Equity too high?
A Plus Biotechnology Co's current Return-on-Tangible-Equity of 12.45% is 98% above median its 10-year median of 6.30. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.03. A Plus Biotechnology Co's value of 12.45% is 208.9% above this industry median. Based on the distribution chart, A Plus Biotechnology Co ranks #175 out of 760 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, A Plus Biotechnology Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, A Plus Biotechnology Co ranks #175 out of 760 companies for Return-on-Tangible-Equity. This places A Plus Biotechnology Co in the top 23% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.03. A Plus Biotechnology Co's value of 12.45% is 208.9% above this benchmark. While the company's 10-year median is 6.30 vs. the industry median of 4.03, A Plus Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.03, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. A Plus Biotechnology Co's current Return-on-Tangible-Equity of 12.45% is 208.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on A Plus Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. A Plus Biotechnology Co's current Return-on-Tangible-Equity is 12.45%, which is 98% above median its own 10-year median of 6.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.26, compared to a current price of NT$74.00 — trading 15.2% below its estimated fair value. The current Return-on-Tangible-Equity is 12.45%, which is 98% above median its 10-year median of 6.30 and 208.9% above the Medical Devices & Instruments industry median of 4.03. A Plus Biotechnology Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current Return-on-Tangible-Equity is 12.45% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?
Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued.
The current stock price of NT$74.00 is trading 15.2% below its estimated GF Value™ of NT$87.26.
GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.
Key valuation signals for TPE:6918:
Return-on-Tangible-Equity: 12.45% (98% above median its 10-year median of 6.30)
GF Value™: NT$87.26 vs. price of NT$74.00 (15.2% below fair value)
Industry Position: 208.9% above the Medical Devices & Instruments median (#175 of 760)
No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
72GF Score
Get the complete analysis for TPE:6918
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6918 has been successfully added to your 
